Human antithrombin III-derived heparin-binding peptide, a novel heparin antagonist

Life Sciences

Volumn 73, Issue 22, 2003, Pages 2793-2806

  Onoue, Satomi ^a,b   Nemoto, Yoshitaka ^a,c   Harada, Sunao ^a   Yajima, Takehiko ^b   Kashimoto, Kazuhisa ^a  

^a Itoham Foods Inc   (Japan)

^b TOHO UNIVERSITY   (Japan)

^c American Peptide Company   (United States)

Author keywords

Anticoagulants; Antithrombin III; Factor Xa; Heparin; Thrombin

Indexed keywords

AGAROSE; ANTITHROMBIN III; HEPARIN; HEPARIN ANTAGONIST; HEPARIN BINDING PROTEIN; THROMBIN;

ARTICLE; BINDING AFFINITY; BINDING SITE; BIOCHEMISTRY; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; ELUTION; HUMAN; PHYSICAL CHEMISTRY; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION;

EID: 0141495007     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(03)00705-7     Document Type: Article

References (36)

1. Bae J., Desai U.R., Pervin A., Caldwell E.E., Weiler J.M., Linhardt R.J. Interaction of heparin with synthetic antithrombin III peptide analogues. Biochemical Journal. 301(Pt. 1):1994;121-129.
2. Bang N.U., Mattler L.E. Sensitivity and specificity of plasma serine protease chromogenic substrates. Haemostasis. 7(2-3):1978;98-104.
3. Blinder M.A., Marasa J.C., Reynolds C.H., Deaven L.L., Tollefsen D.M. Heparin cofactor II: cDNA sequence, chromosome localization, restriction fragment length polymorphism, and expression in Escherichia coli. Biochemistry. 27(2):1988;752-759.
4. Castellot J.J. Jr., Kambe A.M., Dobson D.E., Spiegelman B.M. Heparin potentiation of 3T3-adipocyte stimulated angiogenesis: mechanisms of action on endothelial cells. Journal of Cellular Physiology. 127(2):1986;323-329.
5. 13C nuclear-magnetic-resonance studies. Biochemical Journal. 197(3):1981;599-609.
6. Chen H.C., Brown J.H., Morell J.L., Huang C.M. Synthetic magainin analogues with improved antimicrobial activity. FEBS Letters. 236(2):1988;462-466.
7. Choay J., Lormeau J.C., Petitou M., Sinay P., Fareed J. Structural studies on a biologically active hexasaccharide obtained from heparin. Annals of the New York Academy Sciences. 370:1981;644-649.
8. Choay J., Petitou M., Lormeau J.C., Sinay P., Casu B., Gatti G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochemical and Biophysical Research Communications. 116(2):1983;492-499.
9. Garnier J., Osguthorpe D.J., Robson B. Analysis of the accuracy and implications of simple methods for predicting the secondary structure of globular proteins. Journal of Molecular Biology. 120(1):1978;97-120.
10. 1H NMR spectroscopy. Biochemistry. 26:1987;4403-4408.
11. Greenfield N., Fasman G.D. Computed circular dichroism spectra for the evaluation of protein conformation. Biochemistry. 8(10):1969;4108-4116.
12. Guex N., Peitsch M.C. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis. 18(15):1997;2714-2723.
13. Jin L., Abrahams J.P., Skinner R., Petitou M., Pike R.N., Carrell R.W. The anticoagulant activation of antithrombin by heparin. Proceedings of the National Academy of Sciences U. S. A. 94(26):1997;14683-14688.
14. Jones G.R., Hashim R., Power D.M. A comparison of the strength of binding of antithrombin III, protamine and poly(L-lysine) to heparin samples of different anticoagulant activities. Biochimica et Biophysica Acta. 883(1):1986;69-76.
15. Jorpes E., Edman P., Thaning T. Neutralization of action of heparin by protamine. Lancet. 2:1939;975-976.
16. Kurachi K., Fujikawa K., Schmer G., Davie E.W. Inhibition of bovine factor IXa and factor Xabeta by antithrombin III. Biochemistry. 15(2):1976;373-377.
17. Linhardt R.J., Rice K.G., Kim Y.S., Lohse D.L., Wang H.M., Loganathan D. Mapping and quantification of the major oligosaccharide components of heparin. Biochemical Journal. 254(3):1988;781-787.
18. Maciag T., Mehlman T., Friesel R., Schreiber A.B. Heparin binds endothelial cell growth factor, the principal endothelial cell mitogen in bovine brain. Science. 225(4665):1984;932-935.
19. Matsuzaki K., Nakamura A., Murase O., Sugishita K., Fujii N., Miyajima K. Modulation of magainin 2-lipid bilayer interactions by peptide charge. Biochemistry. 36(8):1997;2104-2111.
20. Mejdoub H., Le Ret M., Boulanger Y., Maman M., Choay J., Reinbolt J. The complete amino acid sequence of bovine antithrombin (ATIII). Journal of Protein Chemistry. 10(2):1991;205-212.
21. Mourey L., Samama J.P., Delarue M., Choay J., Lormeau J.C., Petitou M., Moras D. Antithrombin III: structural and functional aspects. Biochimie. 72(8):1990;599-608.
22. Onoue S., Ohshima K., Endo K., Yajima T., Kashimoto K. PACAP protects neuronal PC12 cells from the cytotoxicity of human prion protein fragment 106-126. FEBS Letters. 522(1-3):2002;65-70.
23. Pratt C.W., Church F.C. Antithrombin: structure and function. Seminars in Hematology. 28(1):1991;3-9.
24. Ragg H. A new member of the plasma protease inhibitor gene family. Nucleic Acids Research. 14(2):1986;1073-1088.
25. Rezaie A.R. Calcium enhances heparin catalysis of the antithrombin-factor Xa reaction by a template mechanism. Evidence that calcium alleviates Gla domain antagonism of heparin binding to factor Xa. Journal of the Biological Chemistry. 273(27):1998;16824-16827.
26. Riesenfeld J., Thunberg L., Hook M., Lindahl U. The antithrombin-binding sequence of heparin. Location of essential N-sulfate groups. Journal of the Biological Chemistry. 256(5):1981;2389-2394.
27. Rosenberg R.D., Damus P.S. The purification and mechanism of action of human antithrombin-heparin cofactor. Journal of the Biological Chemistry. 248(18):1973;6490-6505.
28. Shenoy S., Harris R.B., Sobel M. Development of heparin antagonists with focused biological activity. Current Pharmaceutical Design. 5(12):1999;965-986.
29. Skinner R., Abrahams J.P., Whisstock J.C., Lesk A.M., Carrell R.W., Wardell M.R. The 2.6 A structure of antithrombin indicates a conformational change at the heparin binding site. Journal of Molecular Biology. 266(3):1997;601-609.
30. Skinner R., Chang W.S., Jin L., Pei X., Huntington J.A., Abrahams J.P., Carrell R.W., Lomas D.A. Implications for function and therapy of a 2.9 A structure of binary-complexed antithrombin. Journal of Molecular Biology. 283(1):1998;9-14.
31. Smith J.W., Knauer D.J. A heparin binding site in antithrombin III. Journal of Biological Chemistry. 262(25):1987;11964-11972.
32. Suzuki K., Deyashiki Y., Nishioka J., Kurachi K., Akira M., Yamamoto S., Hashimoto S. Characterization of a cDNA for human protein C inhibitor. A new member of the plasma serine protease inhibitor superfamily. Journal of Biological Chemistry. 262(2):1987;611-616.
33. Thornton S.C., Mueller S.N., Levine E.M. Human endothelial cells: use of heparin in cloning and long-term serial cultivation. Science. 222(4624):1983;623-625.
34. Tollefsen D.M., Majerus D.W., Blank M.K. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. Journal of Biological Chemistry. 257(5):1982;2162-2169.
35. Villanueva G.B. Predictions of the secondary structure of antithrombin III and the location of the heparin-binding site. Journal of Biological Chemistry. 259(4):1984;2531-2536.
36. Wieprecht T., Dathe M., Schumann M., Krause E., Beyermann M., Bienert M. Conformational and functional study of magainin 2 in model membrane environments using the new approach of systematic double-D-amino acid replacement. Biochemistry. 35(33):1996;10844-10853.